Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Antithrombin III · 1 trial · 2 indications
Measurement of postoperative ATIII functional activity at ICU admission
Percentage of subjects with ATIII levels of 58% functional activity or higher at ICU admission
| Arm | Type | Description |
|---|---|---|
| Antithrombin III treatment group | EXPERIMENTAL | Preoperative ATIII supplementation administered immediately after anesthesia induction |
| Control group | NO_INTERVENTION | No preoperative ATIII supplementation administered |
| Name | Type | Description |
|---|---|---|
| Antithrombin III | DRUG | Single dose of antithrombin III sufficient to achieve a preoperative level of 120% |
Inclusion Criteria: * Male or female * At least 18 years of age * Subject needed elective cardiac surgery with cardiopulmonary bypass except for heart transplantation * Subject had a baseline ATIII level of less than 100% and equal to or above 60% * Subject signed the informed consent form * Subjec...
Anti-thrombin III is used for ATIII Deficiency and Acquired Antithrombin III Deficiency. It is being studied in cardiac surgery with cardiopulmonary bypass and in children undergoing open congenital cardiac surgery. The drug is in Phase 2 clinical development.
Anti-thrombin III is developed by Grifols, S.A., a biopharmaceutical company. The company's stock ticker is GRFS. The drug is currently in Phase 2 clinical trials for ATIII Deficiency and Acquired Antithrombin III Deficiency.
Anti-thrombin III is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 trials have been completed, one with 200 participants and another with 45 participants.
Anti-thrombin III has been studied in two completed Phase 2 trials. NCT00823082 examined its use in cardiac surgery with cardiopulmonary bypass in Italy, enrolling 200 participants. NCT02103114 studied it versus placebo in children under 7 months undergoing open congenital cardiac surgery in the United States, enrolling 45 participants.
Anti-thrombin III is also known as Antithrombin III. The drug is being developed by Grifols, S.A. for ATIII Deficiency and Acquired Antithrombin III Deficiency. It is currently in Phase 2 clinical trials.